FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics

FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics